Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Bullish +75

CAH Gains on Q3 Earnings Beat, '26 EPS View Up Despite Revenue Miss

📈 Cardinal Health reported third-quarter fiscal 2026 adjusted EPS of $3.17, beating the consensus estimate of $2.80 by 13.2%.

💰 Adjusted earnings per share represented a 35% year-over-year improvement in the bottom line.

💵 GAAP EPS for the quarter was $1.69 compared to $2.10 in the prior year period.

📉 Sales reached $60.94 billion, reflecting an 11% year-over-year increase but missing consensus estimates by 2.3%.

💊 Pharmaceutical revenues grew 11% to $56.11 billion driven by brand and specialty pharmaceutical sales growth.

🏭 Pharmaceutical profits totaled $784 million, a 18% increase from the previous year due to positive generics program performance.

📦 Global Medical Products and Distribution revenue remained flat at $3.15 billion, partially offsetting lower distribution volumes.

⚠️ The Global Medical Products segment profit dropped 36% to $25 million primarily due to adverse tariff impacts.

💉 At-Home Solutions and Nuclear segments within Global Medical grew significantly with sales up 31% and profit up 34%.

🔄 Gross margin increased to 4.1% of revenues, an improvement of almost 20 basis points year over year.

💸 Operating income decreased 30.3% to $509 million, while adjusted operating income rose 18.5% to $956 million.

🏦 The company ended the quarter with cash and equivalents of $3.94 billion, up from $2.78 billion in the prior quarter.

🚀 Cardinal Health raised its fiscal 2026 adjusted EPS guidance range to $10.70-$10.80 from $10.15-$10.35.

🛠️ The Pharmaceutical segment profit is now expected to grow 22-23% compared to the previous guidance of 20-22%.

💻 Shares of Cardinal Health rose 0.4% in pre-market trading despite a revenue miss but earnings beat.

🏥 Cardinal Health acquired Solaris Health to expand its urology presence, adding over 750 providers across 14 states.

⚡ The company expanded Actinium-225 production capabilities at its Nuclear and Precision Health Solutions Center for Theranostics Advancement.

💰 Management maintained a disciplined capital allocation strategy with debt reduced ahead of schedule and $1 billion in share repurchases.

Bullish Signals
  • Cardinal Health reported Q3 adjusted EPS of $3.17, beating analyst estimates by 13.2% with a full-year improvement of 35% year over year.
  • Pharmaceutical revenues grew 11% to $56.11 billion driven by brand and specialty pharmaceutical sales growth from existing customers.
  • Pharmaceutical profit increased 18% to $784 million due to positive generics program performance and contributions from brand products.
  • Sales in the Nuclear and Precision Health Solutions segment surged 31% year over year, contributing to a 34% profit increase to $179 million.
  • The company raised its fiscal 2026 adjusted EPS guidance to $10.70-$10.80, representing 30-31% growth compared to the previous outlook.
  • Cardinal Health increased its Pharmaceutical segment profit guidance to 22-23% growth and Other segment profit guidance to 36-38% growth.
  • Cash and cash equivalents grew significantly to $3.94 billion from $2.78 billion, while net cash provided by operating activities jumped to $3.48 billion.
  • The company strengthened its balance sheet by reducing debt ahead of schedule and returning $1.0 billion to shareholders via share repurchases and dividends year to date.
  • The acquisition of Solaris Health added over 750 providers in 14 states, expanding The Specialty Alliance's reach to approximately 3,000 providers across 33 states.
  • Shares were up 0.4% in pre-market trading and underperformed the broader market declines, losing only 1.3% year-to-date versus the industry's 6.1% decline.
  • The company is expanding Actinium-225 production capabilities to support next-generation targeted therapies and data-driven healthcare solutions.
Risk Factors
  • While adjusted EPS beat estimates, GAAP EPS actually declined to $1.69 from $2.10 in the year-ago period, indicating underlying profitability headwinds.
  • Total revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%, revealing growth execution challenges despite top-line expansion efforts.
  • Operating income dropped 30.3% year over year to $509 million, a significant deterioration in core profitability that contrasts with adjusted earnings.
  • The Global Medical Products and Distribution segment reported a profit of only $25 million, down 36% from the prior year, primarily due to adverse net impacts from tariffs.
  • Distribution expenses increased 17.3% year over year to $1.54 billion, rising at a faster rate than revenues and squeezing margins.
  • Revenue growth estimates for the Medical segment are conservative, with analysts expecting only 1-3% growth compared to higher growth in other sectors.
  • The company faces competitive pressure as its stock has lost 1.3% year-to-date while the S&P 500 Index has gained 4.5%, underperforming the broader market.
  • Debt reduction and share repurchases, while positive, may limit future strategic acquisitions or capital expenditure if growth slows.
Full Analysis
Cardinal Health, Inc. reported third-quarter fiscal 2026 results that exceeded analyst expectations for earnings per share but fell short on revenue. The company's adjusted EPS reached $3.17, surpassing the Zacks Consensus Estimate of $2.80 by 13.2%, while GAAP EPS stood at $1.69 compared to $2.10 in the prior-year period. Sales totaled $60.94 billion, representing an 11% year-over-year increase but missing estimates by 2.3%. The strong earnings performance was driven primarily by the Pharmaceutical segment, where revenues grew 11% to $56.11 billion and profits rose 18% to $784 million, aided by brand sales growth and positive generic program performance. The Medical Products and Distribution segment contributed mixed results, with revenues of $3.15 billion remaining flat due to lower distribution volumes offset by Cardinal Health brand growth. Despite this, the segment's profit dropped 36% to $25 million, mainly impacted by adverse net tariffs, though specific sub-segments like at-Home Solutions saw a 34% profit increase to $179 million. Overall company cash and cash equivalents increased significantly to $3.94 billion from $2.78 billion in the previous quarter, and operating cash flow surged to $3.48 billion from $877 million year-over-year. Gross margins improved to 4.1%, up 20 basis points, despite a 36% rise in SG&A expenses. Looking ahead, Cardinal Health raised its fiscal 2026 guidance, anticipating adjusted EPS between $10.70 and $10.80, which represents a significant increase from the previous outlook of $10.15 to $10.35. The company projects Pharmaceutical segment revenues to grow 15-17% with segmental profit increasing 22-23%. Strategic initiatives highlighted include the acquisition of Solaris Health, which added over 750 providers to the urology specialty alliance, and continued investment in nuclear medicine capabilities via the expansion of Actinium-225 production. The company also maintained a disciplined capital allocation strategy, having reduced debt and repurchased shares totaling $1.0 billion year-to-date alongside regular dividend payments. Consequently, Cardinal Health's stock gained 0.4% in pre-market trading after reporting these mixed but ultimately positive results for long-term value creation.